[go: up one dir, main page]

ES2099714T3 - Procedimiento de tratamiento endoproteolitico de las proteinas (precursores) y de produccion microbiologica de proteinas. - Google Patents

Procedimiento de tratamiento endoproteolitico de las proteinas (precursores) y de produccion microbiologica de proteinas.

Info

Publication number
ES2099714T3
ES2099714T3 ES90915837T ES90915837T ES2099714T3 ES 2099714 T3 ES2099714 T3 ES 2099714T3 ES 90915837 T ES90915837 T ES 90915837T ES 90915837 T ES90915837 T ES 90915837T ES 2099714 T3 ES2099714 T3 ES 2099714T3
Authority
ES
Spain
Prior art keywords
furina
furine
protein
proteins
endoproteolytic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90915837T
Other languages
English (en)
Other versions
ES2099714T5 (es
Inventor
De Ven Willem Jan Marie Van
Den Ouweland Anna Maria Wi Van
Duijnhoven Johannes Lamber Van
Antonius Johannes Mar Roebroek
Piet Nico Maria Koning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26646599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2099714(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from NL8902651A external-priority patent/NL8902651A/nl
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Application granted granted Critical
Publication of ES2099714T3 publication Critical patent/ES2099714T3/es
Publication of ES2099714T5 publication Critical patent/ES2099714T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/62—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from Aspergillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION SE BASA EN EL DESCUBRIMIENTO DE QUE LA FURINA PERTENECE A LA FAMILIA DE LAS ENZIMAS ENDOPROTEOLITICAMENTE ACTIVAS Y SE REFIERE A UN PROCESO PARA LA DIVISION IN VITRO DE UNA PROTEINA A BASE DE TRATAR LA PROTEINA ANTE LA PRESENCIA DE IONES DE CA (AL CUADRADO) + CON FURINA O CON UNA ENZIMA TIPO FURINA, O CON UN FRAGMENTO ENDOPROTEOLITICAMENTE ACTIVO, UNA PROTEINA DE FUSION O DERIVATIVA DE LA FURINA O DE LA ENZIMA TIPO FURINA. LA INVENCION SE PUEDE UTILIZAR PARA LA PRODUCCION (MICRO)BIOLOGICA DE UNA PROTEINA A BASE DE CULTIVAR CELULAS QUE HAN PASADO POR UNA INGENIERIA GENETICA QUE EXPRESAN UNA PROFORMA DE LA PROTEINA ASI COMO FURINA O UNA ENZIMA TIPO FURINA Y DE SEPARAR LA PROTEINA FORMADA. LA INVENCION SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE UNO O MAS PORTADORES, DILUYENTES O ADYUVANTES FARMACEUTICAMENTE ACEPTABLES ASI COMO UNA CANTIDAD ENDOPROTEOLITICAMENTE ACTIVA DE FURINA O DE UNA ENZIMA TIPO FURINA, O UN FRAGMENTO O DERIVADO DE FURINA O DE UNA ENZIMA TIPO FURINA QUE TIENE UNA ACTIVIDAD ENDOPROTEOLITICA.
ES90915837T 1989-10-25 1990-10-12 Procedimiento de tratamiento endoproteolitico de las proteinas (precursores) y de produccion microbiologica de proteinas. Expired - Lifetime ES2099714T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NL8902651A NL8902651A (nl) 1989-10-25 1989-10-25 Farmaceutisch preparaat met endoproteolytische activiteit; werkwijze voor endoproteolytische processing van eiwitten.
NL8902651 1989-10-25
NL9000917 1990-04-18
NL9000917A NL9000917A (nl) 1989-10-25 1990-04-18 Farmaceutisch preparaat met endoproteolytische activiteit; werkwijze voor endoproteolytische processing van (precursor) eiwitten en voor de (micro) biologische bereiding van eiwitten.

Publications (2)

Publication Number Publication Date
ES2099714T3 true ES2099714T3 (es) 1997-06-01
ES2099714T5 ES2099714T5 (es) 2008-04-01

Family

ID=26646599

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90915837T Expired - Lifetime ES2099714T5 (es) 1989-10-25 1990-10-12 Procedimiento de tratamiento endoproteolitico de las proteinas (precursores) y de produccion microbiologica de proteinas.

Country Status (13)

Country Link
US (1) US5989856A (es)
EP (3) EP0693286A1 (es)
JP (2) JP3191111B2 (es)
AT (1) ATE147437T1 (es)
AU (1) AU6613290A (es)
CA (1) CA2069929C (es)
DE (1) DE69029663T3 (es)
DK (1) DK0497828T4 (es)
ES (1) ES2099714T5 (es)
FI (1) FI105348B (es)
GR (1) GR3023013T3 (es)
NL (1) NL9000917A (es)
WO (1) WO1991006314A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935815A (en) * 1989-10-25 1999-08-10 Katholieke Universiteit Leuven Process for micro biological production of proteins
CA2096418C (en) * 1990-11-26 2001-11-20 Philip J. Barr Expression of pace in host cells and methods of use thereof
US6348327B1 (en) 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
DK52293D0 (es) * 1993-05-05 1993-05-05 Novo Nordisk As
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT404838B (de) 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
US6596526B1 (en) 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
EP1756275A1 (en) * 2004-04-23 2007-02-28 Novozymes A/S Method for obtaining mature protease by enzymatic digestion
JP5485873B2 (ja) * 2007-05-22 2014-05-07 バクスター・インターナショナル・インコーポレイテッド ヒトフューリンのための予備的な精製方法
BR122019022434B8 (pt) 2007-12-27 2021-07-27 Baxalta GmbH método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular
WO2009088713A1 (en) 2007-12-31 2009-07-16 Baxter International Inc. Substantially animal protein-free recombinant furin and methods for producing same
EP2569005A1 (en) 2010-05-12 2013-03-20 INSERM - Institut National de la Santé et de la Recherche Médicale Furin and biologically active derivatives thereof for use in the prevention or treatment of an inflammatory disease
BR112013030880B1 (pt) 2011-06-02 2022-04-12 Takeda Pharmaceutical Company Limited Composição aquosa estabilizada de furina recombinante

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0246709A1 (en) * 1986-05-20 1987-11-25 Stichting Katholieke Universiteit Recombinant DNA and cDNA, mRNA, protein, antibodies, and a method of detecting tumor cells
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells

Also Published As

Publication number Publication date
FI921847L (fi) 1992-04-24
DE69029663D1 (de) 1997-02-20
ES2099714T5 (es) 2008-04-01
ATE147437T1 (de) 1997-01-15
CA2069929A1 (en) 1991-04-26
JP3191111B2 (ja) 2001-07-23
JPH05504051A (ja) 1993-07-01
DK0497828T4 (da) 2008-02-04
EP0497828B1 (en) 1997-01-08
EP0497828A1 (en) 1992-08-12
DE69029663T3 (de) 2008-05-21
WO1991006314A2 (en) 1991-05-16
US5989856A (en) 1999-11-23
FI105348B (fi) 2000-07-31
GR3023013T3 (en) 1997-07-30
DE69029663T2 (de) 1997-09-04
EP0693286A1 (en) 1996-01-24
DK0497828T3 (da) 1997-07-07
FI921847A0 (fi) 1992-04-24
NL9000917A (nl) 1991-05-16
CA2069929C (en) 2002-08-27
JP2001238683A (ja) 2001-09-04
EP0497828B2 (en) 2007-10-03
JP3270760B2 (ja) 2002-04-02
AU6613290A (en) 1991-05-31
EP0885956A1 (en) 1998-12-23
WO1991006314A3 (en) 1991-09-05

Similar Documents

Publication Publication Date Title
ES2099714T3 (es) Procedimiento de tratamiento endoproteolitico de las proteinas (precursores) y de produccion microbiologica de proteinas.
Moura-da-Silva et al. Evidence for heterogeneous forms of the snake venom metalloproteinase jararhagin: a factor contributing to snake venom variability
Trummal et al. A novel metalloprotease from Vipera lebetina venom induces human endothelial cell apoptosis
BRPI0413076B8 (pt) processo analítico para composições de pancreatina e comparáveis
AR036827A1 (es) Queratinocitos utilizables como sustancia biologicamente activa en el tratamiento de heridas
JPH02501618A (ja) タンパク質の代謝的安定性を調節する方法
AR025754A1 (es) Secretasa en la enfermedad de alzheimer, sustratos de la app y sus usos
ES2045081T3 (es) Amplificacion estable de genes en adn cromosonal procariotica.
ES8700320A1 (es) Metodo de obtencion del exprimido de una materia seleccionada que contiene renina.
BR9910251A (pt) Estimulação hematopoiética
WO2006044204A3 (en) Neuronal progenitors from feeder-free human embryonic stem cell culture
ES2060942T3 (es) Terapia genetica utilizando celulas estromicas.
DE69736391D1 (de) Verfahren zur herstellung eines rekombinanten polypeptids unter hinzufügung eines hemmstoffes einer metallabhängigen protease oder chymotrypsins zum zellkulturmedium
DE69009068D1 (de) Methoden und materialien zur expression von varianten von menschlichem plasminogen.
ES2061536T3 (es) Procedimiento para la obtencion de glucosa dehidrogenasa a partir de bacillus megaterium.
ES2043610T3 (es) Procedimiento para la produccion de un polipeptido hibrido del tipo activador de plasminogeno.
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
ES2169036T3 (es) Dipeptidilaminopeptidasa de dictyostelium.
ES2173838T3 (es) Procedimiento para la preparacion fermentativa de l-aminoacidos utilizando bacterias corineformes.
BR0009636A (pt) Preparação de procarboxipeptidase b pancreática, formas iso e muteìnas das mesmas e seu emprego
ATE389029T1 (de) Protease assay zur kontrolle medikamentöser therapie
AU2001249267A1 (en) Methods and compositions for elucidating protein expression profiles in cells
AU740727B2 (en) Activated vitamin K-dependent blood factor and method for the production thereof
Calderara " In vivo" detection of calpain and its structure-activity relationship
Bazalii et al. Apocynin attenuates motility and induces transition from sustained to transient EGF-dependent Akt activation in MCF-7 cells that overexpress adaptor protein Ruk/CIN85

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 497828

Country of ref document: ES